Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Rainmed Medical's 3-Year RORE % for the quarter that ended in Dec. 2025 was -15.55%.
The industry rank for Rainmed Medical's 3-Year RORE % or its related term are showing as below:
HKSE:02297's 3-Year RORE % is ranked worse than 62.93% of 785
companies
in the Medical Devices & Instruments industry
Industry Median: -2.16
vs HKSE:02297: -15.55
Rainmed Medical (HKSE:02297) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Rainmed Medical 3-Year RORE % Related Terms
Rainmed Medical 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Rainmed Medical's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02297 vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Rainmed Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rainmed Medical 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rainmed Medical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Rainmed Medical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Rainmed Medical (HKSE:02297) has a 3-Year RORE % of -15.55 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Rainmed Medical and its competitors. According to the industry distribution chart, Rainmed Medical ranks #494 out of 785 companies in the Medical Devices & Instruments industry, placing it in the top 62.9%.
Is Rainmed Medical's 3-Year RORE % too high?
Rainmed Medical's current 3-Year RORE % is -15.55. Based on the distribution chart, Rainmed Medical ranks #494 out of 785 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Rainmed Medical has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rainmed Medical's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Rainmed Medical ranks #494 out of 785 companies for 3-Year RORE %. This places Rainmed Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Rainmed Medical and its competitors. Rainmed Medical's current 3-Year RORE % is -15.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainmed Medical stock overvalued right now?
Based on GuruFocus' analysis, Rainmed Medical (HKSE:02297) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.16 — trading 98.8% above its estimated fair value. The current 3-Year RORE % is -15.55. Rainmed Medical's overall GF Score™ is 45/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Rainmed Medical (HKSE:02297), the current 3-Year RORE % is -15.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rainmed Medical (HKSE:02297) Overvalued in 2026?
Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued.
The current stock price of HK$0.16 is trading 98.8% above its estimated GF Value™ of HK$0.08.
GuruFocus considers Rainmed Medical to be Significantly Overvalued.
Key valuation signals for HKSE:02297:
3-Year RORE %: -15.55
GF Value™: HK$0.08 vs. price of HK$0.16 (98.8% above fair value)
No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
45GF Score
Get the complete analysis for HKSE:02297
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02297 has been successfully added to your 
